MetaVia (MTVA) Research & Development (2015 - 2026)
MetaVia's (MTVA) quarterly Research & Development came in at $241000.0 in Q4 2025, down 94.06% YoY from $4.1 million in Q4 2024, and down 87.41% on a QoQ basis from $1.9 million in Q3 2025.
MetaVia (MTVA) Research & Development (2015 - 2026) Analysis & Trends
MetaVia (MTVA) has 9 years of Research & Development data on file, last reported at $241000.0 in Q4 2025.
- Quarterly Research & Development fell 94.06% year-over-year to $241000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.8 million (down 68.44% YoY) and the FY2025 annual result came in at $6.8 million, down 68.44% from the prior year.
- Research & Development eased to $241000.0 in Q4 2025, from $1.9 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $8.2 million in Q3 2022 to a low of $241000.0 in Q4 2025.
- A 4-year average of $3.2 million and a median of $2.3 million in 2025 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2024 — Research & Development soared 669.86% — and 2025, when it plunged 94.06%.
- Tracing MTVA's Research & Development over 4 years: stood at $305000.0 in 2022, then soared by 108.85% to $637000.0 in 2023, then surged by 537.05% to $4.1 million in 2024, then sank by 94.06% to $241000.0 in 2025.
- The last three Research & Development figures came in at $241000.0 (Q4 2025), $1.9 million (Q3 2025), and $2.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | MetaVia | 8.72 Mn | -3.92 Mn | - | 3.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.48 Mn |
| Dec 31, 2025 | 241,000.00 |
| Sep 30, 2025 | 1.91 Mn |
| Jun 30, 2025 | 2.32 Mn |
| Mar 31, 2025 | 2.33 Mn |
| Dec 31, 2024 | 4.06 Mn |
| Sep 30, 2024 | 4.52 Mn |
| Jun 30, 2024 | 8.07 Mn |
| Mar 31, 2024 | 4.90 Mn |
| Mar 31, 2023 | 637,000.00 |
| Dec 31, 2022 | 305,000.00 |
| Sep 30, 2022 | 8.21 Mn |
| Jun 30, 2022 | 982,000.00 |
| Sep 30, 2019 | 1.07 Mn |
| Jun 30, 2019 | 1.23 Mn |
| Mar 31, 2019 | 1.39 Mn |
| Dec 31, 2018 | 1.83 Mn |
| Sep 30, 2018 | 3.54 Mn |
| Jun 30, 2018 | 3.96 Mn |
| Mar 31, 2018 | 4.98 Mn |